# Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

> **NCT05570006** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 30 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** ABBV-668

## Key facts

- **NCT ID:** NCT05570006
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-16
- **Primary completion:** 2024-12-23
- **Final completion:** 2024-12-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05570006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05570006, "Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05570006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*